Quantcast

Latest Acetylcholine Stories

d5e5738c0dcb2e74463a0867aebaf17d1
2009-01-23 09:18:29

Duke University Medical System researchers have discovered there are differing taste pathways for nicotine, which could provide a new approach for future smoking-cessation products. "We learned some of nicotine's secrets," said Albino Oliveira-Maia, M.D., Ph.D., a postdoctoral fellow of the Duke Department of Neurobiology. "This is the first study to explore both the peripheral taste pathways activated by nicotine, and how these pathways are integrated in sensory areas of the brain." The...

2009-01-12 01:17:00

MADISON, Wis., Jan. 12 /PRNewswire/ -- Mithridion, Inc., a drug development company focusing on serious Central Nervous System disorders, including Alzheimer's disease (AD), announced today that it held an initial closing of $2.9 million in Series B Preferred Stock financing. The company will use the funds for the clinical development of MCD-386, its lead drug candidate, aimed at stopping or slowing down disease progression and improving memory and cognition in this devastating disorder....

368802e689ea992f70a4767d2b62435a1
2008-11-18 09:25:18

Scientists have identified a relationship between two proteins in the brain that has links to both nicotine addiction and autism. The finding has led to speculation that existing drugs used to curb nicotine addiction might serve as the basis for potential therapies to alleviate the symptoms of autism. The discovery identified a defining role for a protein made by the neurexin-1 gene, which is located in brain cells and assists in connecting neurons as part of the brain's chemical...

2008-10-21 15:00:28

SARASOTA, Fla., Oct. 21 /PRNewswire/ -- A team of world-renowned scientists today announced the launch of Archer Pharmaceuticals, Inc., a new company that will use modern technologies for the identification of novel treatments for Alzheimer's disease. Archer Pharmaceuticals, Inc., led by Chief Executive Officer Michael Mullan, M.B.B.S., Ph.D. and Chief Technical Officer Fiona Crawford, Ph.D., was created based on the groundbreaking research that their team has been conducting in Florida...

2008-10-03 12:00:27

REYKJAVIK, Iceland, Oct. 3 /PRNewswire-FirstCall/ -- deCODE genetics today announced the filing of an investigational new drug (IND) application for DG071, the company's novel small-molecule modulator of phosphodiesterase 4 (PDE4), with the US Food and Drug Administration (FDA). The compound is being developed as a new and potentially safer means of targeting PDE4 to combat memory loss and cognitive deficits associated with Alzheimer's disease and other disorders in which neural signaling...

2008-10-01 15:00:50

U.S. biophysicists say they have clarified the mysterious interaction between cholesterol and the brain's neurotransmitter receptors. University of Pennsylvania scientists said they have provided a new model of behavior for the nicotinic acetylcholine receptor, a well studied protein involved in inflammation, Alzheimer's disease, Parkinson's disease, schizophrenia, epilepsy, the effect of general anesthetics and addiction to alcohol, nicotine and cocaine. As a result of the study,...

2008-09-11 12:00:43

Xel Pharmaceuticals has completed the development of its once-a-week Huperzine A transdermal patch for the treatment of Alzheimer's disease. The prototype transdermal patch can deliver 400800mcg of Huperzine A per day for up to seven days. Huperzine A is said to be a naturally occurring alkaloid found from the club moss Huperzia serrata that has been used for decades in China as a prescription medication for the treatment of dementia. It is a potent, highly selective and reversible...

2008-09-10 12:00:52

Xel Pharmaceuticals, Inc. announced today the completion of the development of its once-a-week Huperzine A transdermal patch for the treatment of Alzheimer's disease (AD). The prototype transdermal patch can deliver 400-800 mcg of Huperzine A per day for up to seven days. Huperzine A is a naturally occurring alkaloid found from the club moss Huperzia serrata that has been used for decades in China as a prescription medication for the treatment of dementia. Huperzine A is a potent, highly...

2008-09-10 06:00:08

TheraGenetics Limited, a personalized medicine diagnostics company that is developing and commercializing a portfolio of pharmacogenetic diagnostic tests to guide and improve the treatment of central nervous system (CNS) disorders, announced today an agreement with King's College London for its participation in the AddNeuroMed Consortium to identify biomarkers for Alzheimer's disease that can be used to determine patient response to medications. TheraGenetics will undertake a pharmacogenetic...

2008-08-20 09:00:22

SAN FRANCISCO, Aug. 20 /PRNewswire/ -- Emerging therapeutic strategies for Alzheimer's disease is the focus of the most recent edition of Neurotech Insights, the leading monthly industry newsletter covering drugs, devices and diagnostics for the brain and nervous system. This month's feature article reviews the competing hypotheses around the cause of Alzheimer's disease including: the beta amyloid theory, tau hypothesis, the APOE4 and vascular theory, anti-inflammatories, memory...


Word of the Day
omadhaun
  • A fool; a simpleton: a term of abuse common in Ireland and to a less extent in the Gaelic-speaking parts of Scotland.
This word is partly Irish in origin.